U.S. pharma big copyright scrapped two experimental weight loss tablets last yr—a after-daily pill, lotiglipron, on account of elevated liver enzymes and a 2 times-every day tablet, danuglipron, on account of solid Unintended effects—but CEO Albert Bourla has mentioned the company is set to “Engage in and acquire” within the obesity Room As